Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIB003 versus evolocumab crossover study in homozygous familial hypercholesterolemia
2019-003611-62Phase 3Completed
- Sponsor
- LIB Therapeutics, LLC
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lerodalcibep and evolocumab in homozygous familial hypercholesterolemia (HoFH) (2 arms), sponsored by LIB Therapeutics, LLC. Primary endpoint: Percent change from baseline in LDL-C. Started Nov 2019; status: completed.
02
Drugs
lerodalcibepevolocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2019-003611-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003611-62.